Abstract
The interaction between the chemokine, CXCL12 and its receptor, CXCR4 is known to be involved in several intractable disease processes, including HIV infection, cancer cell metastasis, leukemia cell progression and rheumatoid arthritis. It is conjectured that this interaction may be an important therapeutic target in all of these diseases, and various CXCR4 antagonists have been proposed as potential drugs. This article describes the development in our laboratory of a number of specific CXCR4 antagonists. Keywords: Cancer metastasis, Chemokine receptor, HIV infection, Leukemia cell progression, Low molecular weight CXCR4 antagonist, Rheumatoid arthritis
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
